TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02959125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NutFish Based Food Supplementation
Description: Cookies contain 500 Calories and 15 gram protein make from nut and ocean fish

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Description: Vitamin A 5000 iu, vitamin D 400 iu, vitamin C 100 mg, vitamin B1 7.5 mg, vitamin B2 3 mg, vitamin B6 10 mg, vitamin B12 10 mcg, fluoride 1 mg, Fe fumarate 91 mg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 400 mcg, Zn 5 mg, Ca lactate 250 mg, copper 0.1 mg, iodine 0.1 mg

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education in Pregnancy Class
Description: Health education on pregnancy, complication, and breastfeeding by research team members

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education in Pregnancy Class
Description: Health education on pregnancy, complication, and breastfeeding by research team members

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Government Food Supplementation
Description: Cookies contain 500 Calories and 5 gram protein make from flour and egg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fe Supplementation
Description: Ferrous Fumarate 60mg and folic acid 0.400 mg
Study: NCT04629040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral wedge insole
Description: Lateral wedge insole for knee osteoarthritis patient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary insole
Description: Ordinary insole
Study: NCT01909856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25mg d1,d3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25mg d1,d3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Granisetron 3mg d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Granisetron 3mg d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10mg d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10mg d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
Study: NCT01937221

Intervention type: OTHER
Intervention: spectral-domain optical coherence tomography (SD-OCT)
Description: Intervention same to all groups.

Intervention type: OTHER
Intervention: spectral-domain optical coherence tomography (SD-OCT)
Description: Intervention same to all groups.

Intervention type: OTHER
Intervention: spectral-domain optical coherence tomography (SD-OCT)
Description: Intervention same to all groups.
Study: NCT03039114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexal
Description: Bendamustine 90 mg/m\^2 administered intravenously at protocol-defined timepoints.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gazyvaro
Description: Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
Study: NCT01060072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate
Description: Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Loteprednol Etabonate
Description: Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
Study: NCT04498793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: On Days 1 and 8 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: On Days 1 and 8 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
Study: NCT01587495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
Study: NCT02484495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program evaluation (impact assessment)
Description: The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.~Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day.
Study: NCT03266068

Intervention type: GENETIC
Intervention: DNA Analysis of Blood Sample
Description: DNA analysis of the genes possibly involved in IBS.

Intervention type: GENETIC
Intervention: DNA Analysis of Blood Sample
Description: DNA analysis of the genes possibly involved in IBS.
Study: NCT02698163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanodiamond reinforced Gutta Percha
Description: Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
Study: NCT03266068

Intervention type: GENETIC
Intervention: DNA Analysis of Blood Sample
Description: DNA analysis of the genes possibly involved in IBS.

Intervention type: PROCEDURE
Intervention: Flexible sigmoidoscopy with colonic biopsies
Description: Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.

Intervention type: PROCEDURE
Intervention: Flexible sigmoidoscopy with colonic biopsies
Description: Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
Study: NCT02698163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gutta Percha
Description: Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gutta Percha
Description: Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
Study: NCT03524170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study: NCT02401503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101
Description: Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
Study: NCT03195166

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FloTrac sensor/Vigileo
Description: blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
Study: NCT04176237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV Dosimetry Laboratory
Description: The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
Study: NCT02452138

Intervention type: OTHER
Intervention: Severe sepsis management

Intervention type: OTHER
Intervention: Severe sepsis management

Intervention type: OTHER
Intervention: Severe sepsis management
Study: NCT04431856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for COVID-19 Parenting Stress (UP-COVID)
Description: UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for COVID-19 Parenting Stress (UP-COVID)
Description: UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHG
Description: Brochure that details techniques for coping with stress.
Study: NCT00002715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin sulfate
Description: A component of the Stanford V regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stanford V regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: A component of the Stanford V regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: A component of the Stanford V regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechlorethamine hydrochloride
Description: A component of the Stanford V regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: A component of the Stanford V regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: A component of the Stanford V regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate
Description: A component of the Stanford V regimen.
Study: NCT02701907

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Study: NCT03335189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASyMS-Can
Description: Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
Study: NCT01377142

Intervention type: DEVICE
Intervention: Laparoscopic sacral hysteropexy
Description: Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance

Intervention type: DEVICE
Intervention: Vaginal mesh hysteropexy
Description: Uphold device used which includes sacrospinous ligament fixation
Study: NCT02272738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
Study: NCT02833779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group exercises
Study: NCT02654184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine position
Description: Anesthesia induction with sevoflurane for the patient while he is in supine position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right lateral position
Description: Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
Study: NCT05631158

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit.
Study: NCT03153436

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Myoinositol

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Myoinositol
Study: NCT01206296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Gemcitabine
Description: Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles
Study: NCT02862366

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling every 6 month following the routine calendar of visit

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling every 6 month following the routine calendar of visit

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling every 6 month following the routine calendar of visit
Study: NCT03033641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation procedure
Description: All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
Study: NCT00938457

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiation therapy
Description: Patients undergo stereotactic body radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implanted fiducial-based imaging
Description: radiation therapy treatment planning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam computed tomography
Description: radiation therapy treatment planning
Study: NCT03107273

Intervention type: OTHER
Intervention: Dynamic cultures of in vitro hematopoietic stem cells
Description: Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis

Intervention type: OTHER
Intervention: Dynamic cultures of in vitro hematopoietic stem cells
Description: Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
Study: NCT03881072

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasounicelastography
Description: Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
Study: NCT03292731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-Hydroxyprogesterone caproate 250mg or 500 mg.
Description: For the pharmacodynamic study, subjects receiving either 250mg or 500 mg dose will be studied to relate the plasma concentration at 26-30 to the rate of sPTB. For the safety study, subjects will be randomized to either the 250mg or 500 mg dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-Hydroxyprogesterone caproate 250mg or 500 mg.
Description: For the pharmacodynamic study, subjects receiving either 250mg or 500 mg dose will be studied to relate the plasma concentration at 26-30 to the rate of sPTB. For the safety study, subjects will be randomized to either the 250mg or 500 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safety study of 500 mg dose.
Description: Subjects randomized to 250 mg or 500 mg dose
Study: NCT03207516

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sourdough --> Brewer's Yeast
Description: Impact of bakery products with sourdough or brewer's yeast on digestive function

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sourdough --> Brewer's Yeast
Description: Impact of bakery products with sourdough or brewer's yeast on digestive function

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brewer's Yeast --> Sourdough
Description: Impact of bakery products with sourdough or brewer's yeast on digestive function

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brewer's Yeast --> Sourdough
Description: Impact of bakery products with sourdough or brewer's yeast on digestive function
Study: NCT02875743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Study: NCT03796897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched protein
Description: Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Habitual diet only
Description: Habitual diet only (no supplementation) for 4 exercise sessions
Study: NCT02608073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
Study: NCT03148509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: DA receptor-mediated drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: DA receptor-mediated drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: DA receptor-mediated drugs
Study: NCT03750058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant test procedure
Description: Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
Study: NCT01718574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help book
Description: Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
Study: NCT00012350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTI
Study: NCT01499498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil and Boceprevir
Description: 25mg once/800mg three times a day
Study: NCT02569931

Intervention type: OTHER
Group type: OTHER
Intervention: Gait analysis
Description: Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.

Intervention type: OTHER
Group type: OTHER
Intervention: Electromyography
Description: Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-operative tracking and pressure measurements
Description: Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements